# Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

> **NCT01005407** · PHASE3 · COMPLETED · sponsor: **Dynavax Technologies Corporation** · enrollment: 2452 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** HEPLISAV and/or Placebo
- **BIOLOGICAL:** Engerix-B

## Key facts

- **NCT ID:** NCT01005407
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-01
- **Final completion:** 2011-05
- **Target enrollment:** 2452 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005407, "Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01005407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*